Barclays PLC Centessa Pharmaceuticals PLC Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Barclays PLC holds 5,302 shares of CNTA stock, worth $86,051. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,302
Previous 350
1414.86%
Holding current value
$86,051
Previous $6,000
1383.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CNTA
# of Institutions
118Shares Held
124MCall Options Held
7KPut Options Held
220K-
Medicxi Ventures Management (Jersey) LTD20MShares$324 Million73.44% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$162 Million99.89% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$157 Million5.81% of portfolio
-
Perceptive Advisors LLC New York, NY6.35MShares$103 Million3.55% of portfolio
-
First Light Asset Management, LLC Edina, MN5.81MShares$94.2 Million9.51% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.53B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...